1 – 20 of 20
- show: 50
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2024
-
Mark
Mortality Rate by Diagnosis in ANCA-Associated Vasculitis Across FAIRVASC Registries
2024) p.187-187(
- Contribution to conference › Abstract
- 2023
-
Mark
Long-term outcomes and prognostic factors for survival of patients with ANCA-associated vasculitis
(
- Contribution to journal › Article
-
Mark
Predictors of hypogammaglobulinemia in ANCA-associated vasculitis after a rituximab-based induction : a multicentre study
(
- Contribution to journal › Article
-
Mark
Data quality and patient characteristics in European ANCA-associated vasculitis registries : data retrieval by federated querying
(
- Contribution to journal › Article
-
Mark
Traditional and Disease-Specific Risk Factors for Cardiovascular Events in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis : A Multinational Retrospective Study
(
- Contribution to journal › Article
- 2022
-
Mark
Data quality in ANCA-associated vasculitis: an analysis of the FAIRVASC registries
2022) 20th International Vasculitis and ANCA workshop(
- Contribution to conference › Abstract
-
Mark
Incidence of Kidney Replacement Therapy and Subsequent Outcomes Among Patients With Systemic Lupus Erythematosus : Findings From the ERA Registry
(
- Contribution to journal › Article
- 2021
-
Mark
Association of venous thromboembolic events with skin, pulmonary and kidney involvement in ANCA-associated vasculitis : A multinational study
(
- Contribution to journal › Article
-
Mark
Rituximab in Membranous Nephropathy
(
- Contribution to journal › Scientific review
- 2020
-
Mark
Effect of Treatment on Damage and Hospitalization in Elderly Patients with Microscopic Polyangiitis and Granulomatosis with Polyangiitis
(
- Contribution to journal › Article
-
Mark
Rituximab in adult minimal change disease and focal segmental glomerulosclerosis - What is known and what is still unknown?
(
- Contribution to journal › Scientific review
- 2019
-
Mark
Proteinase-3 and myeloperoxidase serotype in relation to demographic factors and geographic distribution in anti-neutrophil cytoplasmic antibody-associated glomerulonephritis
2019) In Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 34(2). p.301-308(
- Contribution to journal › Article
-
Mark
Characteristics and Outcomes of Patients With Systemic Sclerosis (Scleroderma) Requiring Renal Replacement Therapy in Europe : Results From the ERA-EDTA Registry
(
- Contribution to journal › Article
- 2017
-
Mark
Patients double-seropositive for ANCA and anti-GBM antibodies have varied renal survival, frequency of relapse, and outcomes compared to single-seropositive patients
(
- Contribution to journal › Article
-
Mark
Association of a TNFSF13B (BAFF) regulatory region single nucleotide polymorphism with response to rituximab in antineutrophil cytoplasmic antibody-associated vasculitis
(
- Contribution to journal › Letter
- 2016
-
Mark
Rituximab for treatment of severe renal disease in ANCA associated vasculitis
(
- Contribution to journal › Article
- 2015
-
Mark
Outcome and Treatment of Elderly Patients with ANCA-Associated Vasculitis.
(
- Contribution to journal › Article
- 2012
-
Mark
Genetically Distinct Subsets within ANCA-Associated Vasculitis
(
- Contribution to journal › Article
- 2011
-
Mark
A cross-sectional study of the Birmingham Vasculitis Activity Score version 3 in systemic vasculitis.
(
- Contribution to journal › Article
-
Mark
Measurement of damage in systemic vasculitis: a comparison of the Vasculitis Damage Index with the Combined Damage Assessment Index
(
- Contribution to journal › Article